QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:CYCN

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

$3.20
+0.12 (+3.90%)
(As of 05:21 PM ET)
Today's Range
$3.20
$3.45
50-Day Range
$2.78
$3.94
52-Week Range
$1.75
$9.60
Volume
18,636 shs
Average Volume
2,989 shs
Market Capitalization
$8.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYCN stock logo

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Stock Price History

CYCN Stock News Headlines

Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CYCN - Cyclerion Therapeutics, Inc.
Cyclerion Shares Rise After Spurned Bid for Assets
Cyclerion Rejects Unsolicited Proposal To Buy Its Assets
See More Headlines
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-5,260,000.00
Pretax Margin
-742.76%

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$4.62 per share

Miscellaneous

Free Float
2,355,000
Market Cap
$8.59 million
Optionable
No Data
Beta
1.83
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed in 2024?

Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of the year. Since then, CYCN stock has decreased by 4.5% and is now trading at $3.20.
View the best growth stocks for 2024 here
.

When is Cyclerion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CYCN earnings forecast
.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($5.20) EPS for the quarter, topping the consensus estimate of ($7.00) by $1.80. The firm earned $0.35 million during the quarter, compared to the consensus estimate of $3 million.

When did Cyclerion Therapeutics' stock split?

Cyclerion Therapeutics shares reverse split on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Cyclerion Therapeutics own?
Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Tyndall Capital Partners L P (6.71%), Vanguard Group Inc. (0.87%), Vanguard Group Inc. (0.96%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Peter M Hecht, Peter M Hecht, Slate Path Capital Lp and Terrance Mcguire.
View institutional ownership trends
.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYCN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners